Association analysis for the muscarinic M1 receptor genetic polymorphisms and Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 1, 2005, Pages 42-45

  Liu, Hsiu Chih ^a,b   Hong, Chen Jee ^a,b   Liu, Tsung Yun ^a   Chi, Chin Wen ^a   Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Age of onset; Alzheimer's disease; Association study; Polymorphism; Type I muscarinic receptor

Indexed keywords

APOLIPOPROTEIN E; MUSCARINIC M1 RECEPTOR;

AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRATIFICATION;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; DISEASE SUSCEPTIBILITY; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, MUSCARINIC; RNA, MESSENGER; STATISTICS; VARIATION (GENETICS);

EID: 10844247067     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080970     Document Type: Article

References (20)

1. Auld DS, Kornecook TJ, Bastianetto S, Quirion R: Alzheimer's disease and the basal forebrain cholinergic system: Relations to betaamyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002;68:209-245.
2. Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D, Jones SV: Muscarinic acetylcholine receptor subtypes: Localization and structure/function. Prog Brain Res 1993;98:121-127.
3. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI: Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-1891.
4. Ladner CJ, Lee JM: Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998;57:719-731.
5. Wang SZ, Zhu SZ, Mash DC, el-Fakahany EE: Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Brain Res Mol Brain Res 1992;16:64-70.
6. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A: Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997;26:341-350.
7. Shiozaki K, Iseki E, Uchiyama H, Watanabe Y, Haga T, Kameyama K, Ikeda T, Yamamoto T, Kosaka K: Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: Relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;67:209-213.
8. Ladner CJ, Lee JM: Reduced high-affinity agonist binding at the M1 muscarinic receptor in Alzheimer's disease brain: Differential sensitivity to agonists and divalent cations. Exp Neurol 1999;158:451-458.
9. Fisher A, Brandeis R, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z: Impact of muscarinic agonists for successful therapy of Alzheimer's disease. J Neural Transm Suppl 2002;62:189-202.
10. Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Muller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM: Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003;10:1-6.
11. Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D, Jones SV: Muscarinic acetylcholine receptor subtypes: Localization and structure/function. Prog Brain Res 1993;98:121-127.
12. Ohara K, Kondo N, Xie D, Tanabe K, Yamamoto T, Kosaka K, Miyasato K, Ohara K: Normal sequences of muscarinic acetylcholine receptors (m1 and m2) in patients with Alzheimer's disease and vascular dementia. Neurosci Lett 1994;178:23-26.
13. Finckh U: The future of genetic association studies in Alzheimer disease. J Neural Transm 2003;110:253-266.
14. Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Tsai SJ: Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003;48:72-76.
15. Hong CJ, Liu TY, Liu HC, Wang SJ, Fuh JL, Chi CW, Lee KY, Sim CB: Epsilon 4 allele of apolipoprotein E increases risk of Alzheimer's disease in a Chinese population. Neurology 1996;46:1749-1751.
16. Liou YJ, Lai IC, Hong CJ, Liu HC, Liu TY, Tsai SJ: Association analysis of the partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant and Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:301-304.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Reports of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
18. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260-12264.
19. Mulugeta E, Karlsson E, Islam A, Kalaria R, Mangat H, Winblad B, Adem A: Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003;960:259-262.
20. Messer WS Jr: The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 2002;19:187-193.